| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_79751aeaa9923745648e5ae7d9c35782 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-38 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-38 |
| filingDate |
1985-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1986-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7396e44a1abb025be0abe55a25e9df09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80741e831ff90a0efd889c27cb445fd8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6b086b83b7ea3a48d26108669f4cb46 |
| publicationDate |
1986-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-4582850-A |
| titleOfInvention |
Topical and systemic treatment of psoriasis using 7-chloro-N-(3,4-dichlorophenyl)-2,3-dihydro-5-hydroxy-1-benzothiepin-4-carboxamide 1,1-dioxide and pharmaceutically acceptable salts thereof |
| abstract |
Psoriasis is treated by the topical or oral administration of an effective endogenous lipoxygenase inhibiting amount of a compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof to a patient in need of the same. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4803197-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004116531-A1 |
| priorityDate |
1985-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |